Introduction {#sec1_1}
============

Renal cell carcinoma (RCC) comprises 2--3% of all adult malignancies and 85% of malignant renal tumors. The highest incidence is found in individuals in the sixth and seventh decades of life, 66 being the median age at diagnosis \[[@B1], [@B2], [@B3], [@B4], [@B5]\]. RCC has a strong propensity to metastasize; 25% of patients initially present with distant metastasis and another 50% develop metastasis during follow-up \[[@B1], [@B6], [@B7]\]. It is the third most frequent neoplasm to metastasize to the head and neck region, preceded only by breast and lung cancer \[[@B1], [@B3], [@B4], [@B5], [@B8], [@B9], [@B10]\]. Although infrequently reported, head and neck regional metastases may be linked to RCC in up to 8--15% of cases \[[@B1], [@B2], [@B4], [@B6], [@B7], [@B8], [@B9]\]. The most affected regions of the head and neck include the paranasal sinuses, larynx, jaws, temporal bones, thyroid gland, and parotid glands. RCC metastases to the nose and paranasal sinuses are the most frequently affected areas, followed by the tongue \[[@B1], [@B3], [@B9], [@B11], [@B12]\]. The most common presenting symptoms to the head and neck region include an enlarging neck mass, epistaxis, anosmia, facial pain, nasal obstruction, and diplopia \[[@B6]\].

RCC is comprised of hypervascular tumors associated with multiple arteriovenous shunts due to the release of vascular endothelial growth factor as well as other angiogenic factors. Given the fact that the kidneys receive 25% of the circulating blood volume, RCC has a high spreading potential via the blood \[[@B12], [@B13]\].

RCC has 5 distinct histologic presentations: clear cell/conventional (75%), papillary (15%), chromophobe (5%), collecting duct (2%), and unclassified (3%). Histopathologically, clear cell RCC typically shows a compact alveolar or solid architecture with varying degrees of cystic changes. RCC characteristically tends to exhibit numerous capillaries and thin-walled blood vessels in the supporting stroma. The cytoplasm is rich in lipids and glycogen; the latter 2 elements dissolve during processing to provide the characteristic clear cytoplasm \[[@B2], [@B7]\]. Immunohistochemical staining helps in this distinction, exhibiting focal cytokeratin positivity (vs. minor salivary gland cancers that show diffuse positivity) and a strong reaction for vimentin \[[@B3]\].

Radiologic diagnosis is based on the vascular nature of the tumor, which shows moderate to marked signal enhancement on contrast CT. If contrast enhancement indicates destruction and lack of tumor calcification, metastatic RCC should be part of the differential diagnosis \[[@B5]\]. Radical nephrectomy is the standard of care for RCC. Palliative care for RCC metastasis is often the treatment of choice. Excision is usually performed to control pain and to manage any potential complications from space-occupying masses in the head and neck region, including the brain \[[@B1], [@B10]\]. RCC does not respond well to radiation therapy, and while chemotherapy (interleukin-2, interferon-α, and 5-fluorouracil) may be useful in cases of residual disease after resection, a positive response is experienced in less than 25% of patients \[[@B2]\]. Radiotherapy can only improve symptomatic relief and increase quality of life for perhaps a few months \[[@B1]\].

The 5-year survival rate for RCC after nephrectomy is 60--75%. Excision of solitary metastatic lesions of RCC following nephrectomy results in a survival rate of 41% at 2 years and 13% at 5 years. The prognosis for patients with multiple RCC metastases is poor, with a 5-year survival rate of 0--7% \[[@B2], [@B4], [@B9], [@B14]\].

Case Report {#sec1_2}
===========

We report on a 62-year-old male who presented to the Ophthalmology Service with VI cranial nerve bilateral paresis, absence of pharyngeal reflex, dysarthria, right tongue deviation, and paralysis to the right side of the face. CT and MRI were performed, with CT showing a large expansive process at the cranial base with clivus and right petrous apex osteolysis (fig. [1](#F1){ref-type="fig"}). Poor enhancement was seen following intravenous contrast injection associated with rhinopharyngeal involvement (fig. [2](#F2){ref-type="fig"}).

An MRI T1 sequence showed a solid isointense expansive process with bilateral internal carotid artery involvement (fig. [3](#F3){ref-type="fig"}). An MRI T2 sequence revealed small hyperintense areas indicative of being cystic in nature or suggestive of central necrosis (fig. [4](#F4){ref-type="fig"}). Ipsilateral side secretions coming from the Eustachian tube indicated the mastoid region had been compromised. An additional MRI T1 sequence following administration of gadolinium contrast material showed moderate enhancement with clear involvement of bilateral internal carotid arteries (fig. [5](#F5){ref-type="fig"}) and the cavernous sinus, posterior ethmoidal sinus, clivus and both petrous apex infiltration. In addition, nasal and posterior superior rhinopharyngeal wall involvement was observed (fig. [6](#F6){ref-type="fig"}).

After imaging analysis, the patient was referred to the ENT service and a biopsy was performed. The diagnosis was clear cell adenocarcinoma and suspicion of renal tumor metastases. The Head and Neck Cancer Committee recommended ultrasonography, which subsequently revealed a heterogeneous echogenic multilobular mass on the right kidney, with irregular contours (fig. [7](#F7){ref-type="fig"}, fig. [8](#F8){ref-type="fig"}, fig. [9](#F9){ref-type="fig"}).

Pelvic and abdominal CT was performed, revealing a large mass on the right kidney with irregular contours and poor definition. Further investigations performed following contrast injection revealed a heterogeneous density with a hypodense central area and some calcifications in thickness (hyperdense deposits in the body of the primary tumor: right kidney) (fig. [10](#F10){ref-type="fig"}). Radiotherapy was recommended, but due to the advanced stage of the disease the patient was enrolled in a palliative care and pain control program.

Conclusion {#sec1_3}
==========

Metastases of malignances in the head and neck are rare. When present, they tend to be very aggressive due to the advance stage of the disease. Multidisciplinary management, clinical experience and high-resolution imaging support are crucial for determining tumor identification, primary tumor localization, and the extent of tumor involvement.
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![MRI, T1 sequence. Isointense mass with bilateral internal carotid artery involvement.](cro-0006-0416-g03){#F3}

![MRI, T2 sequence. Hyperintense central areas suggest cyst degeneration or central necrosis.](cro-0006-0416-g04){#F4}

![MR T1 FSGD (fat saturation and gadolinium). Moderate enhancement and bilateral internal carotid artery involvement.](cro-0006-0416-g05){#F5}
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![HE. Clear cells with poor atypia.](cro-0006-0416-g07){#F7}

![Immunohistochemical stain: vimentin positive.](cro-0006-0416-g08){#F8}

![Right kidney echo tomography: multilobular mass with heterogeneous echogenicity.](cro-0006-0416-g09){#F9}
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